SABCS 2022 | Composite biomarkers predictive of palbociclib + endocrine treatment benefit in early breast cancer

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, talks on the development and validation of composite biomarkers predictive of palbociclib plus endocrine treatment benefit in early breast cancer from the Phase III PENELOPE-B (NCT01864746) and PALLAS (NCT02513394) clinical trials. Both trials investgated palbociclib as part of neoadjuvant treatment in patients intermediate or intermediate and high-risk breast cancer, and neither demonstrated an improvement in patient outcomes. The composite biomarker identified takes into account luminal subtyping as well as a number of genes including HER2 and identified a subgroup of patients benefiting from palbociclib in the neoadjuvant setting. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.